A retrospective comparison of infliximab versus adalimumab as induction and maintenance therapy for Crohn disease

Abstract

Clinical and biochemical outcomes were similar in patients treated with IFX or ADA as induction and maintenance therapy for CD. However, significant reductions were noted in admissions relating to fistulising disease in IFX patients.